Sino Biopharmaceutical (OTCMKTS:SBMFF – Get Free Report) is expected to be announcing its results after the market closes on Wednesday, August 19th. Analysts expect Sino Biopharmaceutical to announce earnings of $0.0177 per share and revenue of $2.8412 billion for the quarter.
Sino Biopharmaceutical Trading Up 6.7%
OTCMKTS SBMFF opened at $0.65 on Tuesday. The business’s 50-day moving average price is $0.62 and its two-hundred day moving average price is $0.72. Sino Biopharmaceutical has a 12 month low of $0.59 and a 12 month high of $1.24.
Sino Biopharmaceutical Company Profile
Sino Biopharmaceutical Limited (OTCMKTS: SBMFF) is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China’s domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.
The company’s product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.
See Also
- Five stocks we like better than Sino Biopharmaceutical
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Sino Biopharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
